Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
IPO Year: 2019
Exchange: NASDAQ
Website: progyny.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2024 | $17.00 | Overweight → Neutral | Analyst |
| 11/13/2024 | $26.00 → $19.00 | Buy → Hold | Truist |
| 9/19/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 8/7/2024 | $37.00 → $24.00 | Buy → Hold | Canaccord Genuity |
| 8/7/2024 | $31.00 → $25.00 | Outperform → Market Perform | Leerink Partners |
| 8/7/2024 | Buy → Neutral | BTIG Research | |
| 7/16/2024 | $36.00 | Mkt Outperform | JMP Securities |
| 5/10/2024 | Overweight → Sector Weight | KeyBanc Capital Markets | |
| 2/26/2024 | $49.00 | Outperform | Leerink Partners |
| 1/3/2024 | $48.00 | Overweight | Barclays |
4 - Progyny, Inc. (0001551306) (Issuer)
4 - Progyny, Inc. (0001551306) (Issuer)
Analyst downgraded Progyny from Overweight to Neutral and set a new price target of $17.00
Truist downgraded Progyny from Buy to Hold and set a new price target of $19.00 from $26.00 previously
JMP Securities downgraded Progyny from Mkt Outperform to Mkt Perform
Canaccord Genuity downgraded Progyny from Buy to Hold and set a new price target of $24.00 from $37.00 previously
BTIG Research downgraded Progyny from Buy to Neutral
Leerink Partners downgraded Progyny from Outperform to Market Perform and set a new price target of $25.00 from $31.00 previously
JMP Securities initiated coverage of Progyny with a rating of Mkt Outperform and set a new price target of $36.00
KeyBanc Capital Markets downgraded Progyny from Overweight to Sector Weight
Leerink Partners initiated coverage of Progyny with a rating of Outperform and set a new price target of $49.00
Barclays initiated coverage of Progyny with a rating of Overweight and set a new price target of $48.00